Cas no 923117-91-3 (2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide)
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide Chemical and Physical Properties
Names and Identifiers
-
- 2-chloro-N-[4-(morpholin-4-ylsulfonyl)benzyl]acetamide
- 2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide
- 923117-91-3
- 2-chloro-N-((4-(morpholine-4-sulfonyl)phenyl)methyl)acetamide
- AKOS000118212
- G38909
- 974-086-1
- 2-chloro-N-(4-(morpholinosulfonyl)benzyl)acetamide
- CS-0241333
- EN300-23244
- Z147651830
- 2-chloro-N-[(4-morpholin-4-ylsulfonylphenyl)methyl]acetamide
-
- MDL: MFCD08444146
- Inchi: 1S/C13H17ClN2O4S/c14-9-13(17)15-10-11-1-3-12(4-2-11)21(18,19)16-5-7-20-8-6-16/h1-4H,5-10H2,(H,15,17)
- InChI Key: XSKGGYDKZGLYLO-UHFFFAOYSA-N
- SMILES: ClCC(NCC1C=CC(=CC=1)S(N1CCOCC1)(=O)=O)=O
Computed Properties
- Exact Mass: 332.0597559Da
- Monoisotopic Mass: 332.0597559Da
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 21
- Rotatable Bond Count: 5
- Complexity: 438
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 0.4
- Topological Polar Surface Area: 84.1?2
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Chemenu | CM482147-250mg |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95%+ | 250mg |
$130 | 2023-02-01 | |
| Chemenu | CM482147-500mg |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95%+ | 500mg |
$213 | 2023-02-01 | |
| Chemenu | CM482147-1g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95%+ | 1g |
$310 | 2023-02-01 | |
| Enamine | EN300-23244-1g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95% | 1g |
$284.0 | 2023-09-15 | |
| Enamine | EN300-23244-5g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95% | 5g |
$825.0 | 2023-09-15 | |
| Enamine | EN300-23244-10g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95% | 10g |
$1224.0 | 2023-09-15 | |
| Enamine | EN300-23244-0.05g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95% | 0.05g |
$46.0 | 2024-06-19 | |
| Enamine | EN300-23244-0.1g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95% | 0.1g |
$73.0 | 2024-06-19 | |
| Enamine | EN300-23244-0.25g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95% | 0.25g |
$105.0 | 2024-06-19 | |
| Enamine | EN300-23244-0.5g |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide |
923117-91-3 | 95% | 0.5g |
$197.0 | 2024-06-19 |
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide Related Literature
-
Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
-
Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
-
Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
Additional information on 2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide
Research Brief on 2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide (CAS: 923117-91-3)
2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide (CAS: 923117-91-3) is a synthetic compound that has garnered significant attention in recent chemical and biomedical research due to its potential applications in drug discovery and development. This research brief aims to provide an up-to-date overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.
Recent studies have highlighted the role of 2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide as a key intermediate in the synthesis of novel pharmacologically active molecules. Its unique structural features, including the morpholine sulfonyl group and chloroacetamide moiety, make it a versatile building block for the development of targeted therapies. Researchers have explored its utility in the design of enzyme inhibitors, particularly those targeting sulfotransferases and other sulfur-metabolizing enzymes.
In the context of medicinal chemistry, several research groups have investigated the compound's potential as a precursor for anticancer agents. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide exhibited promising activity against various cancer cell lines, with particular efficacy observed in breast and prostate cancer models. The mechanism of action appears to involve interference with cellular signaling pathways related to cell proliferation and apoptosis.
From a synthetic chemistry perspective, recent advancements have focused on optimizing the production process of 923117-91-3. A team at MIT developed a novel catalytic system that improves the yield and purity of the compound while reducing environmental impact. This innovation, published in ACS Sustainable Chemistry & Engineering, represents an important step toward scalable production for research and potential clinical applications.
Pharmacokinetic studies conducted in 2024 have provided valuable insights into the compound's absorption, distribution, metabolism, and excretion (ADME) properties. These findings, reported in Drug Metabolism and Disposition, suggest that 2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide demonstrates favorable bioavailability and metabolic stability, making it an attractive candidate for further drug development.
Ongoing research is exploring the compound's potential in treating neurological disorders. Preliminary data from animal models indicate that certain derivatives may modulate neurotransmitter systems involved in Parkinson's disease and depression. However, these findings require further validation through clinical trials before any definitive conclusions can be drawn.
In conclusion, 2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide (923117-91-3) represents a promising chemical entity with diverse potential applications in pharmaceutical development. Continued research into its biological activities and optimization of its derivatives may yield important therapeutic breakthroughs in the coming years. The compound's versatility as a synthetic intermediate and its demonstrated biological activities make it a valuable focus for ongoing chemical and biomedical research.
923117-91-3 (2-chloro-N-{[4-(morpholine-4-sulfonyl)phenyl]methyl}acetamide) Related Products
- 379255-30-8(2-chloro-N-[3-(morpholine-4-sulfonyl)phenyl]acetamide)
- 606136-31-6(Piperazine, 1-(methylsulfonyl)-4-[4-(4-morpholinylsulfonyl)benzoyl]- (9CI))
- 35959-60-5(2-chloro-N-[4-(morpholine-4-sulfonyl)phenyl]acetamide)
- 105206-48-2(1,7,13-Trioxa-4,10,16-triazacyclooctadecane-3,11-dione,4,10-dimethyl-16-[(4-methylphenyl)sulfonyl]-)
- 654682-86-7(4-(Morpholine-4-sulfonyl)-benzoyl chloride)
- 852399-79-2((4-morpholinosulfonylphenyl)methanamine)
- 606136-28-1( )
- 712344-24-6(2-{[4-(morpholine-4-sulfonyl)phenyl]formamido}acetic acid)
- 933989-32-3(3-(morpholine-4-sulfonyl)phenylmethanamine)
- 606136-30-5( )